ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0075

Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis

Yuen Tsang1, Marjolaine Gauthier-Loiselle2, Vienica Funtanilla3, Hayley Germack3, Ameur Manceur4, Stephanie Liu2, Martin Cloutier2, Patrick Lefebvre2 and Sumeet Panjabi5, 1Janssen Scientific Affairs, LLC., Sacramento, CA, 2Analysis Group, Inc., Montréal, QC, Canada, 3Janssen Scientific Affairs, LLC, Titusville, NJ, 4Analysis Group, Inc, Boston, MA, 5Analysis Group, Inc., Titusville, NB, Canada

Meeting: ACR Convergence 2022

Keywords: Administrative Data, population studies, pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Connective tissue disorders (CTDs) are the most frequent diseases associated with pulmonary arterial hypertension (PAH), accounting for 11% – 28% of PAH cases. A better understanding of real-world treatment patterns could help identify potential areas for improvement in the management of CTD-related PAH; thus, this study assessed PAH treatment patterns in this population in the US.

Methods: Adult patients initiated on a PAH treatment (index date: 1st initiation date) were identified from Optum Clinformatics® Data Mart Databases (10/01/2015-09/30/2021). Patients had ≥1 inpatient or ≥2 outpatient PAH diagnosis claims and ≥6 months of continuous insurance eligibility without PAH treatment before the index date (i.e., baseline period). Eligible patients were categorized into mutually exclusive cohorts: (1) CTD+PAH: had ≥1 inpatient or ≥2 outpatient CTD diagnosis claims, with ≥1 claim before/on the index date; or (2) PAH: no CTD diagnosis at any time during baseline or follow-up. Treatment patterns were assessed from the index date to the earliest of death, end of continuous insurance eligibility, or end of data availability. A treatment regimen was defined as all PAH agents observed within 60 days of the 1st agent; a ≥90-day gap with no PAH agents indicated treatment discontinuation. Kaplan-Meier (KM) analysis of persistence (time to 1st treatment change) and time to combination therapy was performed.

Results: Among 728 patients in the CTD+PAH cohort and 4,023 patients in the PAH cohort, average follow-up was 18.8 and 19.6 months, respectively. Mean age was 64.2 and 69.1 years in the CTD+PAH and PAH cohorts, with 85.7% and 60.8% female, respectively. For both cohorts, the most common 1st treatment regimens observed were sildenafil (CTD+PAH: 38.7%; PAH: 51.5%), tadalafil (10.0%; 9.4%), and macitentan (8.1%; 5.4%) in monotherapy. Sildenafil, tadalafil, and macitentan were also the most frequent agents included in any of the first 3 treatment regimens (Figure 1). Combination therapy was more frequent in the CTD+PAH cohort than in the PAH cohort (any regimen: 40.9% vs 27.2%; 1st treatment regimen: 26.9% vs 18.5%; 2nd: 52.8% vs 42.0%; 3rd: 55.2% vs 48.5%; Figure 1). KM analysis showed that patients in the CTD+PAH cohort were more likely to be initiated on combination therapy at any time post-index (Figure 2). The vast majority of patients had cardiologist, pulmonologist, and/or rheumatologist visits, but time to combination therapy was similar regardless of the type of specialist visits. Treatment persistence was similar across cohorts and first 3 treatment regimens, with persistence rates ranging from 42.6% to 49.7% at 12 months (Figure 3).

Conclusion: Compared to PAH patients, CTD+PAH patients were younger and more likely to be female. Treatment patterns were generally similar between the CTD+PAH and PAH cohorts, though combination therapy was more frequent in the CTD+PAH cohort. Both cohorts may benefit from broader use of all available PAH treatment classes, including combination therapy to target the nitric oxide, endothelin, and prostacyclin pathways. Our findings also highlight the need to understand low persistence rates with PAH therapies.

Supporting image 1

Abbreviations: CTD: connective tissue disorder; ERA: endothelin receptor antagonist; PAH: pulmonary arterial hypertension; PDE5i: phosphodiesterase type 5 inhibitor; PPA, prostacyclin pathway agent; SGC: soluble guacylate cyclase inhibitor.
Note:
[1] All agents received are listed regardless of whether they were used as monotherapy or combination therapy.

Supporting image 2

Abbreviations: CI: confidence interval; CTD: connective tissue disorder; PAH: pulmonary arterial hypertension.

Supporting image 3

Abbreviations: CTD: connective tissue disorder; PAH: pulmonary arterial hypertension.
Note:
[1] Persistence was calculated as the time from the initiation of treatment regimen to the first PAH-related treatment change observed (i.e., treatment discontinuation, treatment switch, treatment augmentation, or treatment drop), whichever occurred first. Patients who remained on treatment were censored at the end of the patient follow-up.


Disclosures: Y. Tsang, Janssen; M. Gauthier-Loiselle, Janssen; V. Funtanilla, None; H. Germack, Janssen Scientific Affairs, LLC; A. Manceur, Janssen; S. Liu, Janssen; M. Cloutier, Janssen; P. Lefebvre, Janssen Scientific Affairs, LLC; S. Panjabi, Janssen.

To cite this abstract in AMA style:

Tsang Y, Gauthier-Loiselle M, Funtanilla V, Germack H, Manceur A, Liu S, Cloutier M, Lefebvre P, Panjabi S. Real-World Treatment Patterns Among Patients with Connective Tissue Disorder–Related Pulmonary Arterial Hypertension in the United States: A Retrospective Claims-Based Analysis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/real-world-treatment-patterns-among-patients-with-connective-tissue-disorder-related-pulmonary-arterial-hypertension-in-the-united-states-a-retrospective-claims-based-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/real-world-treatment-patterns-among-patients-with-connective-tissue-disorder-related-pulmonary-arterial-hypertension-in-the-united-states-a-retrospective-claims-based-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology